Total Funding
58
63
Total FundingSeries B raised
Growth Score 58 in past quarter
-4 pts
Heat Score 63 in past quarter
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
74683
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing.
- Roly Foulkes: Chief Scientific Officer
Jonathan M. Rigby: President & CEOPast Role: Zogenix, Co Founder and VP Business Development
About the Company
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. Its mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.
Revolo Biotherapeutics
was founded in 2011 and formerly known as Immune Regulation.
